US 12,257,265 B2
Cyclic dinucleotide prodrug molecule, preparation method therefor and application thereof
Zhen Xi, Tianjin (CN); Zhenghua Wang, Tianjin (CN); and Dan Wang, Tianjin (CN)
Assigned to SHENZHEN YING BIOPHARMACEUTICAL CO., LTD, Shenzhen (CN)
Appl. No. 17/422,137
Filed by SHENZHEN YING BIOPHARMACEUTICAL CO., LTD., Shenzen (CN)
PCT Filed Jan. 10, 2020, PCT No. PCT/CN2020/071329
§ 371(c)(1), (2) Date Jul. 9, 2021,
PCT Pub. No. WO2020/143740, PCT Pub. Date Jul. 16, 2020.
Claims priority of application No. 201910023472.1 (CN), filed on Jan. 10, 2019.
Prior Publication US 2022/0125821 A1, Apr. 28, 2022
Int. Cl. C08B 37/00 (2006.01); A61K 31/7088 (2006.01); A61P 35/00 (2006.01); C07H 1/00 (2006.01); C07H 19/213 (2006.01); C07H 21/04 (2006.01)
CPC A61K 31/7088 (2013.01) [A61P 35/00 (2018.01); C07H 1/00 (2013.01); C07H 19/213 (2013.01); C07H 21/04 (2013.01)] 11 Claims
 
1. A cyclic dinucleotide prodrug molecule, wherein the cyclic dinucleotide prodrug molecule has any one of structures represented by formula (1) to formula (10):

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein, in formula (1) to formula (10),
both B1 and B2 are adenine;
both X1 and X2 are —H;
R1, R2, R3 and R4 are the same and are selected from the group consisting of substituted or unsubstituted aliphatic hydrocarbon groups of C1-C6, substituted or unsubstituted aromatic hydrocarbon groups of C6-C11 and five-membered or six-membered heterocyclic groups; and the substituents optionally present in R1, R2, R3 and R4 are selected from the group consisting of C1-C5 alkyl groups.